Antiretroviral chemoprophylaxis before exposure is a promising approach for the prevention of human immunodeficiency virus (HIV) acquisition.
We carried out a longitudinal and cross-sectional analysis of depressive symptomatology in iPrEx, from the randomized placebo controlled arm study.
In this report from the GBD 2015, we provide national estimates of levels and trends of HIV/AIDS incidence, prevalence, coverage of antiretroviral therapy.
The effect of HIV pre-exposure prophylaxis (PrEP) depends on uptake, adherence, and sexual practices. We aimed to asess these factors in a cohort of HIV-negative people at risk of infection.